Anixa Biosciences, Inc.
ANIX
$3.09
-$0.17-5.22%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.79% | -17.16% | -7.69% | -18.85% | 17.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.07% | -32.18% | -13.38% | -6.18% | 3.67% |
| Operating Income | 9.07% | 32.18% | 13.38% | 6.18% | -3.67% |
| Income Before Tax | 6.56% | 31.22% | 11.54% | 2.34% | -7.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.56% | 31.22% | 11.54% | 2.34% | -7.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -10.00% | -42.11% | -43.90% | -17.14% | -3.23% |
| Net Income | 6.52% | 31.10% | 11.12% | 2.18% | -7.17% |
| EBIT | 9.07% | 32.18% | 13.38% | 6.18% | -3.67% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 8.71% | 32.00% | 11.99% | 4.44% | -3.58% |
| Normalized Basic EPS | 8.63% | 31.97% | 11.64% | 4.35% | -3.54% |
| EPS Diluted | 8.71% | 32.00% | 11.99% | 4.44% | -3.58% |
| Normalized Diluted EPS | 8.63% | 31.97% | 11.64% | 4.35% | -3.54% |
| Average Basic Shares Outstanding | 2.35% | 1.32% | 0.90% | 2.39% | 3.48% |
| Average Diluted Shares Outstanding | 2.35% | 1.32% | 0.90% | 2.39% | 3.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |